Comparison of Nicotine Replacement Therapy and Electronic Cigarettes for Smoking Cessation in Pakistan
A Randomized Controlled Trial (RCT) to Compare Efficacy of Nicotine Replacement Therapy (NRT) Versus Electronic Cigarettes (EC) for Quitting Tobacco Smoking in Pakistan
Smoking is prevalent in Pakistan, and a large proportion of the adult population smokes cigarettes or uses other forms of tobacco. Smoking cessation programmes are not well established, and the few centres that offer cessation, only provide basic support without stop-smoking medicines or other aids that can help people quit. Internationally approved stop-smoking treatments like nicotine replacement therapy (NRT) are available in larger cities, but they are very expensive. This makes it difficult for the general population to use NRT to aid in their desire to quit smoking. In the past few years, the use of electronic cigarettes (EC) has increased manifold. These devices are freely available and are offered in a wide variety of types and flavours. EC are also cheaper compared to NRT, which makes them affordable for most smokers. EC are not considered smoking cessation tools and are not used or recommended by cessation services. This study wants to compare EC with NRT to see which treatment is more successful in helping people quit smoking. The premise is that EC are more effective than NRT. The study also wants to determine the cost of using EC compared to that of NRT, when used for quitting smoking.
The study will have a total of 438 participants who will be assigned randomly (by chance) to two groups: NRT and EC. 219 participants will be provided with NRT, and 219 with EC. The participants will be adult smokers presenting at designated smoking cessation centres who are seeking help in quitting smoking. The main focus of the study is to see if EC are more successful than NRT in helping people quit smoking at the end of one year.
This research will provide useful information on the effectiveness and safety of EC and help develop a smoking cessation policy tailored to the population of Pakistan.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
The use of tobacco in its various forms remains the most common cause of preventable deaths in the world. Every year, 8 million people worldwide die of tobacco-related diseases. The highest burden (80%) is in underdeveloped and developing countries like Pakistan. Pakistan is a country with the fifth-highest burden of tobacco use in the world, with more than 15.6 million adult smokers. 21.9% of adult males and 3.4% of adult females are current cigarette smokers. In Pakistan, every year, around 160,000 lives are lost to tobacco use, and the impact on the economy is more than 1 billion dollars.
Despite this, smoking cessation services are not well established and are limited to a few facilities, predominantly in urban centres. These facilities don't have well-established cessation support programmes, and only provide basic behavioural support. Smoking cessation medicine like Nicotine replacement therapy (NRT) is available in Pakistan but very expensive. Over the past decade, the use of EC has increased in many countries around the world. Evidence suggests that current smokers use EC to reduce the number of cigarettes smoked per day, and ex-smokers use EC most commonly for cessation purposes and to prevent relapse. EC use in Pakistan has also become more common in the past few years. Electronic cigarettes are readily available and significantly cheaper than NRT. EC have great potential as stop-smoking aids; however, EC are not prescribed or recommended for this purpose in any of the smoking cessation centres. The purpose of this study is to evaluate the efficacy, safety, and cost-effectiveness of EC versus NRT for smoking cessation in the adult population of Pakistan.
Design:
The study is a pragmatic, parallel, open-label, randomized controlled trial of NRT with EC. Participants will be adult smokers who are willing to quit and have no preference for NRT or EC. 438 participants will be enrolled. A baseline assessment will be carried out to determine the demographic profile (age, sex, location, socioeconomic measures like income status, education, and employment. A detailed smoking history, including numbers of cigarettes smoked per day, history of quitting, quit attempts, past use of NRT, and past use of EC, will be reviewed. A complete medical examination by qualified clinicians will be conducted to determine eligibility for the study. Eligible participants will be randomly assigned to one of two treatment arms: EC or NRT, with 219 participants in each arm. The study will be conducted in 10 cessation clinics (SCC) across six districts of Pakistan. The NRT arm will be given a combination therapy of a nicotine patch and a faster-acting oral product of their choice (gum or lozenge). The EC arm will be provided with a refillable, 3rd generation EC device and a choice of 3 e-liquid flavours: tobacco, menthol, and fruit. Enough e-liquid will be provided to last until the next supply which will be after an interval of 4 weeks. Further supplies of e-liquids will be provided based on participants preferences. Both arms will be given supplies for 12 weeks and provided with standard behavioural support. The primary outcome measure is self-reported sustained smoking cessation at 52 weeks (one year). This will be verified by carbon Monoxide (CO) validation. A level of less than 8 ppm will be considered abstinent. Secondary outcome measures are CO-validated self-reported sustained abstinence at 24 weeks, self-reported 7-day point prevalence abstinence at 4, 24 and 52 weeks, change in the number of cigarettes smoked per day, time to relapse, and frequency and severity of adverse effects. An analysis of the average cost of treatment per participant will also be conducted.
The analysis for each outcome will use intention-to-treat (ITT) principles. For the primary analysis, the proportion of people who remain abstinent at 52 weeks (1 year) will be determined, and a comparison will be done between the NRT and the EC groups. Because the data variables are categorical, Chi-squared test will be used for significance testing. In our secondary analysis, we will examine time to relapse using Kaplan-Meier curves with Log Rank test for significance testing and Cox regression for Hazard Ratio analysis. We will compare the RCT groups using Chi-squared and logistic regression analyses for the proportion of participants that remained abstinent at 4 weeks and 24 weeks. Rates of adverse reactions will also be compared between arms using Chi-squared tests. The trial will include a cost comparison of total cost of ownership to see which method is the cheaper method, which can then be viewed in relation to their respective quit rates.
Discussion:
This will be the first randomized controlled trial comparing the effectiveness of NRT with EC in Pakistan. Pakistan does not have a national tobacco cessation policy or programme. No research has been conducted to determine the best options available for tobacco cessation in Pakistan. This study is important as it will provide an opportunity to develop Pakistan's first evidence-based smoking cessation policy, which can lead to the development of a comprehensive tobacco cessation programme.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fouad Aslam, MPH
- Phone Number: 00447494700290
- Email: projectdirector@strategichealthresearch.org.uk
Study Contact Backup
- Name: Aftab Ahmad, MA
- Email: projectmanager@strategichealthresearch.org.uk
Study Locations
-
-
-
Islamabad, Pakistan, 44000
- Health Research Consulting
-
Contact:
- Muhammad Aftab Ahmad, MA
- Email: projectmanager@strategichealthresearch.org.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults (18 years or older).
- Current-smokers presenting to a cessation clinic expressing a desire to quit smoking.
- Has capacity to consent.
- Can read and understand the instructions in Urdu and/or English and follow the study instructions and procedures.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Currently using EC or NRT products.
- Already enrolled in another similar study.
- Not willing to quit.
- Patients who have had a recent cardiovascular event like unstable angina, stroke or myocardial infarction in the past 2 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Nicotine Replacement Therapy (NRT)
The arm will comprise participants that receive NRT.
The NRT used will be combination therapy; transdermal Nicotine patches will be combined with faster-acting oral products like gum or lozenges.
The strength of nicotine patches will be from 7 to 21 mg, and for gum or lozenges, the strength will be 1-4 mg.
Usage will be in the form of a daily nicotine patch and ad libitum use of the faster-acting lozenge to curb nicotine cravings.
Participants will be provided with a 12-week supply of NRT.
|
NRT will be in the form of combination therapy with a transdermal nicotine patch (7, 14, or 21mg) and an oral product: either gum or lozenge in 1, 2, or 4mg strength.
Other Names:
|
|
Experimental: Electronic Cigarettes (EC)
Participants randomised to the EC group will be supplied with an EC starter kit.
The kit will consist of a personal vaping device with an integrated battery.
Three commonly used flavours of e-liquid (tobacco, menthol, and fruit flavours) will be provided.
All e-liquids will have a nicotine concentration of 18-20 mg/ml.
EC will be provided for a total of 12 weeks.
|
The intervention consists of the use of an Electronic cigarette device namely the Vaporesso Gen Air 40 Vape Kit.
This is a complete kit including the EC device, integrated battery, refillable tank, charging cable, coil replacements and user manual.
Three e-liquid flavours will be provided; tobacco, menthol and fruit flavour.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Carbon Monoxide (CO) validated sustained abstinence at 52 weeks (1 year)
Time Frame: 52 weeks from Target Quit day (TQD).
|
The primary outcome measure will be a biochemically (carbon monoxide) validated abstinence from smoking measured at 52 weeks (1 year) post target quit day.
|
52 weeks from Target Quit day (TQD).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biochemically verified sustained smoking abstinence at 24 weeks after the Target Quit Day
Time Frame: 24 weeks from Target Quit Day.
|
This outcome measure will be a biochemically (Carbon Monoxide) validated abstinence of smoking measured at 24 weeks post target quit day.
|
24 weeks from Target Quit Day.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-reported 7-day point prevalence abstinence at 4, 24 and 52 weeks.
Time Frame: This self-reported 7-day point prevalence will be conducted at 4, 24 and 52 weeks post target quit day.
|
This will consist of self reported abstinence of smoking "not a puff" in the 7 days leading to the measurement.
|
This self-reported 7-day point prevalence will be conducted at 4, 24 and 52 weeks post target quit day.
|
|
Adverse reactions
Time Frame: Adverse reactions will be recorded on 1, 4, 8, 24 and 52 weeks post TQD.
|
Any adverse reactions or adverse events experienced by the participants.
|
Adverse reactions will be recorded on 1, 4, 8, 24 and 52 weeks post TQD.
|
|
Change in number of cigarettes smoked per day (CPD).
Time Frame: CPD will be measured at 1, 4, 8, 24 and 52 weeks post TQD.
|
In those participants who are not abstinent, cigarettes smoked per day will be noted to determine if there has been any change in the mean number of CPD from the baseline.
|
CPD will be measured at 1, 4, 8, 24 and 52 weeks post TQD.
|
|
Product satisfaction rating
Time Frame: This will be measured at 1, 4, 8, 24 and 52 weeks post TQD.
|
Participants will be asked to rate their satisfaction with using an EC or NRT in comparison with cigarettes.
Satisfaction will be measured on a scale (Product Satisfaction scale) from 1 to 5, with 1 being the lowest and 5 the highest satisfaction rating.
|
This will be measured at 1, 4, 8, 24 and 52 weeks post TQD.
|
|
Intervention cost per participant
Time Frame: 12 weeks from Target Quit day.
|
The average intervention cost per participant will be calculated.
Each treatment has two components: behavioural support and cost of the smoking cessation aid.
Behavioural cost is the same for both groups and will be provided by the cessation clinics.
The trial will provide both NRT and EC for a period of 12 weeks.
Total cost of both NRT and EC supplies will be determined.
This will be divided by the total number of participants utilizing that treatment to get the average cost per participant.
This will enable a comparison of the expenses for the cessation intervention.
|
12 weeks from Target Quit day.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Muzaffar Malik, MPH, Head of Statistics
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- QUITS 3.1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.